Payment overview · 2025
General Payments
$948.76
49 reported records · 6 companies
Healthcare provider profile · identity verified
William Wei Ming Chen, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN PABLO, CA · NPI 1851498372
Verified facts
What the public records show
CMS Open Payments records show William Wei Ming Chen, MD received $948.76 in general payments during 2025 across 49 reported records.
Novo Nordisk Inc accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Linzess, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tezspire by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $227.50 | 24.0% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $216.71 | 22.8% | 6 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $177.13 | 18.7% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $172.24 | 18.1% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $139.29 | 14.7% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $15.89 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $909.20 | 48 |
| Education | $39.56 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $181.93 | 8 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $177.13 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $172.24 | 22 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $117.37 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $99.34 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $85.34 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $85.34 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $53.89 | 6 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.29 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.29 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 51 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 108 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
108 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
89 | 23 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
51 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 946 | 286 |
| Amlodipine Besylate | Amlodipine Besylate | 761 | 204 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 730 | 103 |
| Metformin Hcl | Metformin Hcl | 551 | 169 |
| Metoprolol Succinate | Metoprolol Succinate | 417 | 124 |
| Losartan Potassium | Losartan Potassium | 404 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 399 | 134 |
| Lisinopril | Lisinopril | 374 | 109 |
| Diclofenac Sodium | Diclofenac Sodium | 351 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 321 | 77 |
| Simvastatin | Simvastatin | 297 | 74 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 281 | 118 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 277 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 253 | 81 |
| Furosemide | Furosemide | 250 | 65 |
| Gabapentin | Gabapentin | 245 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 60 |
| Diazepam | Diazepam | 197 | 29 |
| Omeprazole | Omeprazole | 182 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 65 |
| Trazodone Hcl | Trazodone Hcl | 181 | 43 |
| Eliquis | Apixaban | 169 | 42 |
| Nifedipine Er | Nifedipine | 156 | 38 |
| Ibuprofen | Ibuprofen | 147 | 60 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 146 | 52 |
| Jardiance | Empagliflozin | 141 | 52 |
| Allopurinol | Allopurinol | 135 | 45 |
| Atenolol | Atenolol | 129 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 47 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 126 | 33 |
| Lorazepam | Lorazepam | 125 | 38 |
| Ondansetron Hcl | Ondansetron Hcl | 123 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 45 |
| Glipizide | Glipizide | 117 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 117 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 40 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 111 | 89 |
| Linzess | Linaclotide | 108 | 30 |
| Meclizine Hcl | Meclizine Hcl | 107 | 60 |
| Finasteride | Finasteride | 104 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 104 | 33 |
| Januvia | Sitagliptin Phosphate | 102 | 27 |
| Potassium Chloride | Potassium Chloride | 101 | 22 |
| Naproxen | Naproxen | 100 | 31 |
| Lactulose | Lactulose | 91 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 91 | 21 |
| Alendronate Sodium | Alendronate Sodium | 90 | 22 |
| Rybelsus | Semaglutide | 89 | 23 |
| Pregabalin | Pregabalin | 88 | 25 |
| Myrbetriq | Mirabegron | 87 | 19 |
| Amoxicillin | Amoxicillin | 86 | 69 |
| Baclofen | Baclofen | 85 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 19 |
| Trulicity | Dulaglutide | 81 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 24 |
| Donepezil Hcl | Donepezil Hcl | 75 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 75 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 24 |
| Famotidine | Famotidine | 72 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 70 | 23 |
| Carvedilol | Carvedilol | 69 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 19 |
| Meloxicam | Meloxicam | 63 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 17 |
| Xarelto | Rivaroxaban | 61 | 15 |
| Clonazepam | Clonazepam | 60 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 49 |
| Ozempic | Semaglutide | 59 | 17 |
| Temazepam | Temazepam | 58 | 15 |
| Glimepiride | Glimepiride | 57 | 18 |
| Metformin Hcl Er | Metformin Hcl | 56 | 19 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 54 | suppressed |
| Prednisone | Prednisone | 54 | 33 |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 52 | 21 |
| Farxiga | Dapagliflozin Propanediol | 51 | 14 |
| Gemtesa | Vibegron | 51 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 19 |
| Celecoxib | Celecoxib | 49 | 22 |
| Promethazine Hcl | Promethazine Hcl | 49 | 11 |
| Sertraline Hcl | Sertraline Hcl | 48 | 11 |
| Levofloxacin | Levofloxacin | 46 | 38 |
| Cromolyn Sodium | Cromolyn Sodium | 45 | 17 |
| Vascepa | Icosapent Ethyl | 45 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Ezetimibe | Ezetimibe | 43 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | 11 |
| Lovastatin | Lovastatin | 42 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 11 |
| Clotrimazole | Clotrimazole | 39 | 28 |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Levetiracetam | Levetiracetam | 39 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 39 | 15 |
| Doxepin Hcl | Doxepin Hcl | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Belsomra | Suvorexant | 37 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | 17 |
| Colchicine | Colchicine | 36 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 36 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 23 |
| Spironolactone | Spironolactone | 32 | 11 |
| Alprazolam | Alprazolam | 31 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | 13 |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Ssd | Silver Sulfadiazine | 29 | 20 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 28 | 23 |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 12 |
| Telmisartan | Telmisartan | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | 14 |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 24 | suppressed |
| Fluocinonide | Fluocinonide | 24 | 12 |
| Nystatin | Nystatin | 23 | suppressed |
| Sulindac | Sulindac | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 21 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Lacosamide | Lacosamide | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | 15 |
| Diclofenac Potassium | Diclofenac Potassium | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Roflumilast | Roflumilast | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 13 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Tezspire | Tezepelumab-Ekko | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tivicay | Dolutegravir Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $948.76 · 49 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CREON, FARXIGA, FASENRA, GEMTESA, IBSRELA, LINZESS, Ozempic, QULIPTA, REZDIFFRA, Rybelsus, UBRELVY | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error